At the American College of Cardiology’s 59th annual scientific session in Atlanta this week, Abbott released results of a Phase 2 clinical trial of its bioresorbable vascular scaffold (BVS). In this 30 day trial, the new stenting technology has led to no thrombosis, no ischemia-driven target lesion revascularization, and a rate of major adverse cardiac events was only 2 percent.
From the announcement:
This second phase of the ABSORB clinical trial (Cohort B) enrolled 101 patients from 12 centers in Europe, Australia and New Zealand, and incorporates device enhancements designed to improve deliverability and vessel support.Abbott is the only company with long-term, three-year clinical data on a complete patient set evaluating the safety and performance of a fully bioresorbable drug eluting scaffold.
Abbott’s investigational BVS is made of polylactide, a proven biocompatible material that is commonly used in medical implants such as dissolving sutures. The bioresorbable technology is designed to restore blood flow by opening a clogged vessel and providing support until it is healed. Once the vessel can remain open without the extra support, the bioresorbable scaffold is designed to be slowly metabolized by the body, and is completely dissolved over time. Since a permanent implant is not left behind, a vessel treated with BVS has the ability to ultimately move, flex and pulsate similar to an untreated vessel. The potential to restore these naturally occurring vessel functions, or vascular restoration therapy, is what makes Abbott’s BVS unique in the field of cardiology.